Open access
Sep 2026
The SGLT2i Treatment Gap in UK Primary Care: A Cross-Sectional RWE Study of Prescribing in Clinical Practice.
AIMS Sodium-glucose co-transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisat...
Chelsea Stefanska, R. Chung, Salman Ramjaun et al.
· Diabetes, obesity and metabo... · 0 citations